IMUX

#3592
Immunic, Inc. - Common Stock
15.4 0 USD
-0.06%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
15.40
15.40
Jahresspanne
0.51
17.43
Tagesänderung
-5.52%
Monatliche Änderung
+9.22%
6 month change
+1455.56%
Jahresänderung
+1778.05%
Vorheriger Schlusskurs
16.3 0
Open
15.4 0
Tief
15.4 0
Hoch
15.4 0
Volumen
6
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
IMMUNIC, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
IMMUNIC, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
IMMUNIC, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K

IMMUNIC, INC. current report, Q2 FY2024

Full document

Business Context and Reporting Period

This Form 8-K reports on the annual meeting of stockholders held by IMMUNIC, INC. on June 11, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol IMUX.

Key Financial Metrics

This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

The filing details the outcomes of three proposals voted upon by stockholders. A total of 90,079,016 shares were entitled to vote, with 59,921,013 shares present, constituting a quorum.

  • Proposal 1: Election of Class I Directors
    • Dr. Daniel Vitt: Elected with 43,559,455 votes FOR and 6,322,678 votes WITHHELD.
    • Dr. Duane Nash: Elected with 43,433,233 votes FOR and 6,448,900 votes WITHHELD.
    • Both directors will serve until the 2027 annual meeting.
  • Proposal 2: Ratification of Independent Auditor
    • BakerTilly US, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
    • Votes: 59,535,850 FOR, 281,381 AGAINST, 103,782 ABSTAIN.
  • Proposal 3: Say on Pay (Non-Binding Advisory Vote)
    • Stockholders approved the named executive officer compensation.
    • Votes: 47,604,179 FOR, 2,218,350 AGAINST, 59,604 ABSTAIN.

Guidance, Outlook, and Risks

This filing does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It is strictly a disclosure of the results of the stockholder vote.

Key Facts for Investor Verification

  • Verify the tenure of the newly elected directors (Dr. Vitt and Dr. Nash) through the 2027 annual meeting.
  • Confirm the appointment of BakerTilly US, LLP as the auditor for the fiscal year ending December 31, 2024.
  • Note the significant number of shares withheld for the director elections (approx. 6.3 million each) relative to the "For" votes.
  • Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.

Nachrichten